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When transplantation started all organs were retrieved from patients immediately after cardio-respiratory arrest, i.e. from non-
heart-beating donors. After the recognition that death resulted from irreversible damage to the brainstem, organ retrieval rapidly
switched to patients certified dead after brainstem testing. These heart-beating-donors have become the principal source of organs
for transplantation for the last 30 years. The number of heart-beating-donors are declining and this is likely to continue, therefore
cadaveric organs from non-heart-beating donor offers a large potential of resources for organ transplantation. The aim of this study
is to examine clinical outcomes of non-heart-beating donors in the past 10 years in the UK as an way of decreasing pressure in the
huge waiting list for organs transplantation.
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The imbalance between supply of organs for transplan-
tation and demand for them is widening all over the world.
In the United Kingdom (UK) the figures are not different,
by the end of December 2004 there were over 6000 peo-
ple on the active waiting list for organ transplantation. Re-
cent data suggest that over 400 of these people will die each
year before a new organ becomes available.1
When transplantation started all organs were retrieved
from patients immediately after cardio-respiratory arrest, i.e.
from non-heart-beating donors (NHBDs). After the recog-
nition that death resulted from irreversible damage to the
brainstem by Harvard Medical Committee2 and the subse-
quent introduction in 19763 of direct brainstem testing to de-
termine when death has occurred, organ retrieval rapidly
switched to patients certified dead after brainstem testing.
These heart-beating-donors (HBDs) have become the prin-
cipal source of organs for transplantation for the last 30 years.
The number of HBDs are declining and this is likely
to continue for two major reasons: fewer young people are
dying as a result of severe injury or cathastrophic cerobro-
vascular events4, and improvements in diagnosis and man-
agement of severe brain injuries mean that fewer fulfil the
brainstem testing criteria.
Although numbers of NHBDs are slowly increasing,
they still accounted for only 85 of 750 (11.3%) UK cadav-
eric donors in 2004-2005.5
The fundamental problem with NHBDs is warm
ischemia which may lead to suboptimal transplanted organ
function. Developments in organ protection will only lead
to more successful outcomes from NHBD if strategies can
be divised to keep warm ischaemia times as short as pos-
sible.
The aim of this study is to examine clinical outcomes
of NHBDs in the past 10 years in the UK as an way of
decreasing pressure in the huge waiting list for organs trans-
plantation.
A literature review was performed based on a Medline
(Pubmed from 1997 to 2006) search to identify articles on
clinical NHBDs in the UK.
Information on the rates of primary non-function (PNF),
delayed graft function (DGF), acute rejection, graft and
patient survival were registred. Also NHBDs technique,
perfusion and recipient immunosupression were mentioned.
All centres have developed programmes based on the
Maastricht protocol,6 which includes the following princi-
ples:122
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1. approval by local medical ethics committee,
2. diagnosis of death by doctors who are independent of
the transplant team,
3. the 10-min rule (after declaration of cardiac death, the
body is left untouched for a period of 10 min prior in-
tervention),
4. rapid in situ cooling using a catheter inserted into the
aorta, and organ retrieval using standard surgical tech-
niques. Declaration of cardiac death implies irrevers-
ible cessation of heart function and the 10-min hands-
off period ensures the process of irreversible brain death
has begun.
We also recorded the criteria for exclusion of NHBDs,
the Maastricht classification, the current criteria for both
brain-stem death for HBDs and cardiac death for NHBDs,
and finally ethics and legal issues involved in the NHBDs
transplantation.
The first International Workshop in Maastricht7
defined four categories of NHBD:
UNCONTROLLED
Category I – includes victims of accident and suicide
( some centers exclude suicide victims from their programs
) who are found dead at the scene and resuscitation is
deemed pointless (e.g. fatal cervical spine fracture). These
are the worst group of potential donors because of the un-
known primary warm ischemic time.
Category II – donors are mostly victims of sudden car-
diac (the majority) or cerebral catastrophe who are brought
to emergency departments while being resuscitated by am-
bulance personnel or who died in the department. Other
sources include patients suffering isolated brain injury, an-
oxia and stroke, and victims of major trauma who died soon
after hospital admission.
CONTROLLED
Category III – encompasses patients who are dying,
often on an intensive care unit. These are the patients await-
ing cardiac arrest where the treating clinicians have decided
to withdraw treatment and not commence resuscitation for
various reasons.
Category IV – comprises patients who suffer unex-
pected cardiac arrest during or after determination of brain
death.
Ethics and Legal Issues
There is an increasing worldwilde discrepancy between
Table 1 - Non-Heart-Beating Donors - Maastricht
classification7
Description
I Dead on arrival Uncontrolled
II Unsuccessful resuscitation Uncontrolled
III Awaiting cardiac arrest Controlled
IV Cardiac arrest while brain dead (death during Controlled
procurement; death duringexplantation)
Table 2 - Criteria for exclusion of non-heart-beating donors8
1. Cardiac and circulatory arrest does not last longer than 40 minutes.
2. The patient is between 16 and 60 years old.
3. The patient does not belong to a high risk group for immunodeficiency
virus (HIV), or hepatitis B or C infection. There should be no signs of
intravenous drug abuse.
4. The patient has no history of primary kidney disease, uncontrolled
hypertension, or complicated insulin-induced diabetes mellitus (IDDM).
There are no signs of intravascular coagulation with anuria and no signs
of malignancy other than a primary (non-metastatic) cerebral tumor.
5. There are no signs of sepsis or serious infection.
6. Patients who have died after assisted suicide or euthanasia are excluded
from some protocols.
Table 3 - Criteria for brainstem death apply to heart-beating
donors8
1. The underlying pathologic lesion should be understood;
2. There should be no pharmacologic, metabolic, or hormonal influence;
3. Pupillary, corneal, occulo-cephalic, vestibule-occular, and gag reflexes
should be absent;
4. No pain response to stimulation in the distribution of the fifth cranial
nerve; and
5. A re-breathing test with 100% oxygen should be delivery to maintain
satisfactory oxygenation, while ventilation is switched off. The rise in
arterial pCO2 should not stimulate respiration.
# These tests are performed by two experienced clinicians on two separate
occasions.
Table 4 - Criteria for cardiac death apply for non-heart-
beating donors8
1. Deep coma
2. Absence of pulse
3. ECG evidence of asystole
# Cardiac death in the context of potential organ donation is defined as
occurring after 30 minutes of unsuccessful cardiopulmonary resuscitation
under hospital conditions.
# Resuscitation must include external cardiac massage, intubation,
ventilation, defibrillation (if indicate), and appropriate intravenous
medication.
# Unsuccessful means that these measures did not achieve spontaneous
contractile cardiac activity or peripheral circulation.123
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the availability of, and need for organs allografts. It has
been estimated that the number of donor organs could rise
by 25% through the expanded use of NHBD 9 making it
inevitable in an era of universal shortage of donors.
All transplant procurement strategies come with an ethi-
cal dimension but this particular process raises multiple
concerns, not least of which is ambiguity as to the timing
and definition of death.
The principal ethical issues concerning NHBDs pro-
grams are the use of in situ perfusion to consent the diag-
nosis of death by cardiac rather than brain-stem criteria,
and at what time after pronouncement of death the in situ
cooling should be started (dead donor rule).
English law does not require consent for prolonged ven-
tilator support or placement of the double-balloon triple-
lumen (DBTL) catheter, but catheter placement is an in-
vasive procedure and the family members may not wish
for this10.
The dead donor rule11 is pivotal to NHBD organ dona-
tion and states that the donor should not be killed by the
act of donation (i.e. the donor must be dead by cardiac cri-
teria at the time of retrieval). This became relevant when
a decision is taken to discontinue life support measures in
a patient who does not meet the criteria for brain-stem
death and raises the question of when death should be pro-
nounced after cardiac arrest 12.
There is a period when the patient is dead by cardiac
criteria but not by brain-stem criteria13 and 10 minutes is
considered sufficient for the discrepancy to be corrected.
There has been considerable debate over the length of time
that the patient should be left14. For ideal preservation the
kidneys should be perfused as soon as the 10-minute wait-
ing period is over.
These considerations were taken into account at the
Maastricht workshop (1995). The conclusions of this dis-
cussions was that it was safer to apply the dead-donor rule
only after a 10-minute period of asystole7,15. There can be
little doubt that after normothermic ischaemia for this pe-
riod, it would be impossible to restore myocardial func-
tion and there will be irreversible loss of all neurological
function. Then, the criteria for cardiac and brain death will
have been satisfied simultaneously.
Warm Ischaemia Renal Injury
The period of warm ischaemia is usually defined as the
time between cardiac arrest and the start of cardiopulmo-
nary resuscitation.
This could more accurately be described as the abso-
lute warm time because there may be other less obvious
periods of warm ischaemia. The efficacy of external car-
diac massage is achieving renal perfusion is not definitely
known and will vary according to how well resuscitation
is performed. It is likely that a degree of renal warm is-
chaemia is common during cardiopulmonary resuscitation
and this could be described as relative warm time.
Conversely cardiac massage and ventilation which are
effective in oxygenating the kidneys after a period of cir-
culatory standstill, may also be deleterious by initiating the
reperfusion injury syndrome.
Warm ischaemia is known to be a major determinant
of renal function after kidney transplantation. However, the
amount of reversible warm ischaemic injury that the hu-
man kidney can sustain is still not known for certain. Most
human NHBD kidney transplant protocols exclude kidneys
which such prolonged warm times, the usual cutoff being
in the of 30 to 45 minutes16,17.
Renal allografts from controlled NHBDs sometimes
function immediately suggesting that the human kidney tol-
erates short periods of warm ischaemia quite well18. In un-
controlled NHBDs the warm time is not always accurately
known. It may need to be determined by taking a history
from relatives, ambulance staff, and medical personnel and
in some cases this will provide only an approximate esti-
mate.
Surgical Technique
1. Leicester Model for NHBD
(In situ kidney perfusion/Cooling and kidney retrieval
in NHBD)
NHBDs kidneys were perfused and cooled in situ us-
ing a DBTL aortic catheter placed via femoral artery cut-
down in the groin. The technique as described originally
by Garcia-Rinaldi et al19, involves insertion of the DBTL
catheter into the abdominal aorta via femoral arteriotomy.
Inflation of the caudal balloon at the aorta bifurcation and
inflation of the cranial balloon isolates the segment of aorta
from which the renal arteries originate (vertebral level L1).
A plain abdominal radiograph can be taken to show the
position of the catheter, which is radio-opaque.
Wheatley et al20 modification is to mix a small amount
of Conray (May and Baker, Dagenham, UK) radio-contrast
dye with saline injected into the balloons to allow easier
identification of the balloons on radiography. Using a mix-
ture of Conray and saline in a ratio 1:10 rather than neat
Conray makes injection of the viscous liquid much easier.
The balloons were inflated with radiographic contrast
medium, and the positioning checked by plain abdominal
x-ray20.
The system was vented by placing a Foley catheter into124
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the inferior vena cava via the right femoral vein. Follow-
ing in situ renal perfusion the NHBD was transferred to
an operating theatre for bilateral donor nephrectomy.
The perfusion fluid used for NHBD was a 10 to 20 L
Marshall’s hyperosmolar citrate solution at 4 C infused un-
der gravity and all kidneys were held in static ice storage
before transplantation.
2. Newcastle upon-Tyne Model for NHBD
(NHBD retrieval ; pumping perfusion system)
In situ organ perfusion was performed by cannulating
the femoral artery using a DBTL cannula (TXF Medical,
High Wycombe, UK). The preservative solution was cold
(4-8 C) heparinized (1000 IU/L) Marshall’s solution. The
venous venting was through placement of a cannula into
the femoral vein. No radiological confirmation of place-
ment was done. After retrieval the kidneys were cold stored
and transported to the Hospital where machine perfusion
and viability assessment were carried out21.
Pumping perfusion system
A Belco BL 760 blood pump module was used for
perfusion. One pump in the system provided fluid to the
renal artery and the other retrieved it through a heat ex-
changer. The temperature of the system was maintained
between 4 and 9 C. The pump was capable of delivering a
flow rate of 28-480ml/min and pressure were maintained
at 45-60 mm Hg. Thus a closed system of perfusion was
achieved.
A viable kidney tends to have a flow rate of more than
50 ml perfusate/minute per 100 g of kidney and a glutath-
ione S-transferase level less than 200 IU/L per 100 g kid-
ney22.
3. Cambridge Model for NHBD
Following certification of death on the ward, the donor
was transported to the operating theatre. Laparotomy was
performed, a large bore (22F) aortic cannula inserted and
the kidneys were perfused in situ with at least 3L of cold
University of Wiscosin (UW) solution containing 20 000
units of heparin per litre.
The supra-coeliac aorta was cross-clamped to facilitate
perfusion of the kidneys and the venous system was de-
compressed via inferior vena cava. To provided additional
cooling, 2 L of crushed frozen saline were applied around
the kidneys during perfusion. Donor nephrectomy was then
performed23.
4. London Model for NHBD
An interval of 15 minutes after cardiac arrest was al-
ways allowed before cold in situ perfusion or crash retrieval
was commenced. All donors were cooled using Soltran Kid-
ney Perfusion Solution (Baxter Medical, Houston, TX,
USA) with an additive of 20,000 IU of heparin via femo-
ral access using a DBTL inserted into the femoral artery.
Cannulas were placed only after consent of relatives was
given.
The kidneys of the controlled donors were perfused via
rapid aortic cannulation after laparotomy or crash retrieved
with no flush and thereafter perfused with ice-cold solu-
tion on the bench 24.
Pulsatile kidney perfusion with the RM3 pump (Water
Medical Systems, Rochester, MN, USA) for organ assess-
ment and preservation of up to 12 hours was used.
RESULTS
During ten-year period analysed, NHBDs were used
mainly for kidney transplantation in four centres in the UK
as summarized in (Table 5).
NHBDs in the UK centres according to the Maastricht
classification are shown in (Table 6).
Comparing NHBD with HBD the results of PNF, only
3 out of 24 articles have shown significant differences. As
far as DGF is concern 8 out of 24 articles have shown sig-
nificant differences. Acute rejection was reported signifi-
cant in only 1 out of 24 articles (Table 7).
Graft survival was equal for 1, 2,3 and 5 years when
comparing NHBD with HDB except in 1 article that has
shown significant differences in 3 and 5 years time, (Ta-
ble 8).
Patient survival was equal in 1, 3 and 5-years when
comparing NHBD with HBD as shown in (Table 9).
United Kingdom centres and variations of NHBDs tech-
nique, use of double-ballon triple-lumen, machine
perfusion, type of organ perfusion solution as well as
immunossupression are demonstrated in (Table 10).
DISCUSSION
Cadaveric organs from NHBD have been used for dec-
ades. Since the introduction of “brain-stem death” criteria
in 1968, NHBDs have been largely abandoned in favor of
brain-dead donors47
NHBD offers a large potential of resources for renal
transplantation. The process of graft selection involves a
significant number of potential grafts being discarded be-
cause they are judged to be nonviable. The reported dis-125
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card rate of kidneys from NHBD is significant, with esti-
mates ranging from 50 to 65% with uncontrolled donors48.
NHBD programs remain unpopular despite the poten-
tial to increase the donor pool by up to 30%49. A number
of legal, ethical and logistic reasons as well as medical con-
cerns are responsible for this and have even compromised
existing NHBD programs50.
Legal and ethical issues such as cannulation of the
femoral vessels for in situ cooling prior to consent by the
relatives and an undefined interval of no-touch between
cardiac arrest, declaration of death and organ resuscitation/
preservation efforts remain an unsolved problem in the
United Kingdom. If relatives were present the consent rate
for organ donation after cardiac arrest was more than 70%.
In addition, the logistic requirements for a successful,
financially efficient NHBD program are immense and re-
quire good planning, management and organization. Trans-
plant surgeons and coordinators must be within close reach
of potential donor locations in emergency departments, in-
tensive care units, hospital wards, and hospices. Further-
more a sufficient number of trained staff members are re-
quired to share a rota for ininterrupted on-call cover. This
might be possible only for a large transplant units or par-
ticularly dedicated centers. Organ preservation by perfusion
is an additional issue that requires further expertise and is
expensive21,51 but it might be the only reliable technique for
assessing the viability of NHBD kidneys and marginal do-
nors organs52
The 125 NHBD transplants performed in 2005-2006 (82
kidneys only; 36 kidney/liver; 1 kidney, thoracic & liver,
2 kidney, liver & pancreas and 4 liver only) rose 44% com-
paring with 87 NHBD in 2004-2005 but still represent a
Table 6 - Non-heart-beating donors in England centres according to the Maastricht classification.
Centre NHBD* not mentioned NHBD Uncontrolled NHBD Controlled NHBD Total
category (n=365) Category  I e II (n=575) Category III e IV (n=398) (n=1334)
Cambridge - 0 42 42
Leicester 144 144 20 308
London 202 8 40 250
Newcastle upon-Tyne 19 178 201 398
Cambridge, Leicester, London, - 217 68 285
Newcastle upon-Tyne
Leicester, Newcastle upon-Tyne - 24 27 51
*NHBD-non-heart-beating donor
Table 5 - England non-heart-beating donors transplant details
Author Year Centre No. patients Organ
Nicholson et al25 1997 Leicester 30 Kidney
Butterworth et al26 1997 Leicester 37 Kidney
Nicholson et al27 2000 Leicester 77 Kidney
Balupuri et al 21 2000 Newcastle upon-Tyne 15 Kidney
Balupuri et al 28 2001 Newcastle upon-Tyne 28 Kidney
Metcalfe et al 29 2001 Leicester 72 Kidney
Gok et al30 2002 Newcastle upon-Tyne 43 Kidney
Gerstenkorn et al31 2002 London 202 Kidney
Gok et al32 2002 Newcastle upon-Tyne 46 Kidney
Sudhindran et al23 2003 Cambridge 42 Kidney
Gok et al33 2003 Newcastle upon-Tyne 25 Kidney
Brook et al34 2003 Leicester 55 Kidney
Gerstenkorn et al35 2003 London 41 Kidney
Gok et al36 2004 Newcastle upon-Tyne 72 Kidney
Brook et al37 2004 * 285 Kidney
Gok et al38 2004 Newcastle upon-Tyne 02 Kidney
Wilson et al 39 2005 Newcastle upon-Tyne and Leicester 51 Kidney
Bains et al40 2005 Leicester 37 Kidney
Navarro et al 41 2006 Newcastle upon-Tyne 05 Kidney
Gok et al42 2006 Newcastle upon-Tyne 19 Kidney
Navarro et al 43 2006 Newcastle upon-Tyne 81 Kidney
Sohrabi et al44 2006 Newcastle upon-Tyne 05 Kidney
Sohrabi et al 45 2006 Newcastle upon-Tyne 36 Kidney
Muiesan et al46 2006 London 07 Liver
*Leicester, Cambridge, London, Newcastle upon-Tyne (combined results of renal NHBD transplantation in the UK from 1988-2001126
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small proportion of the total transplant activity on the UK53.
The average NHBD retrieval rate for 2001 was 1.3 mil-
lion population (pmp) for the four centres reported here.
This compares with an average national rate for HBD kid-
neys of 23.5 pmp (United Kingdom Transplant Data54. Al-
though the number of NHBD transplants is small the po-
tential is greater; the most encouraging figures come from
Daemen et al (55) who report 40% of their kidneys were ac-
counted for by NHBDs.
Varty et al49 reported 38% of donors were NHBD in
1991 and later Nicholson56 reported that NHBD accounted
for 21% of transplant activity. Light et al57 stated that the
number of NHBD transplant opportunities equals that of
HBD whilst other authors have suggested that there are
Table 7 - Comparation of the results of NHBD/HBD in England relating to primary non-function, delayed graft function
and acute rejection.
Author NHBD/HBD PNF(%) DGF(%) AR(%)
NHBD/HBD NHBD/HBD NHBD/HBD
Nicholson et al25 30/114 3/13(s) 25/87(s) 48/27(s)
Butterworth et al26 37/91 11/1(s) 100/28(s) 27/36(ns)
Nicholson et al27 77/224 9.1/2.7(s) 84.3/21(s) 28.6/32.6(ns)
Balupuri et al21 15/nm 6.6/- 66.6/- nm
Balupuri et al28 28/nm 3.57/- 91.6/- nm
Metcalfe et al29 72/192 7/4(ns) 80/19(s) 24/31(ns)
Gok et al30 43/nm - - -
Gerstenkorn et al31 202/nm 21.8/- 82.3/- 13.1/-
Gok et al32 46/46 8.7/2.2 94.9/41(s) 52.2/41.3(ns)
Sudhindran et al23 42/84 0/2 50/17(s) 33.3/40.5(ns)
Gok et al33 25/nm 2/nm 75/nm -
Brook et al 34 55/69 5/3 93/17 24/23(ns)
Gerstenkorn et al35 41/0 14.6 80 -
Gok et al36 72/nm 7.85/- 75.6/- 41.4/-
Brook et al37 285/0 15 79.7 41
Gok et al38 2/0 0/0 100/0 100/0
Wilson et al39 51/nm 2/nm 7/nm -
Bains et al40 37/75 0/0 31/8(s) 7/27(ns)
Navarro et al41 81/- nm nm nm
Gok et al42 19/15 nm 57.9/45.5(s) 36.8/20(s)
Navarro et al43 5/- nm nm nm
Sohrabi et al44 5/- 0/- 80/- nm
Sohrabi et al45 36/- 6.3/- nm 35/-
Muiesan et al46 07/0 0 0 3
s-significant; ns- not statistically significant; nm- not mentioned; nhbd-non-heart-beating donor;hbd-heart-beating donor; pnf-primary non-function;dgf-
delayed graft function;ar-acute rejection.
Table 8 - Graft survival in NHBD in England.
1 y(%) 2 y(%) 3 y(%) 5 y(%)
Nicholson et al25 NHBD 78 75 73 -
HBD 90 85 82
Butterworth et al26 NHBD 73 73 73 -
HBD 83** 79** 77**
Nicholson et al27 NHBD 85** 87** 87** 79**
HBD 85 82 80 75
Balupuri et al21 NHBD 91.7 - - -
Balupuri et al28 NHBD 88.1 - - -
Metcalfe et al29 NHBD 81 - 77 73
HBD 86** 78** 65**
Gok et al30 NHBD 89.6 - - -
HBD 91.4**
Gerstenkorn et al31 NHBD 86.9 - 75.5 65.5
Gerstenkorn et al35 NHBD - - 82.9 -
Brook et al34 NHBD 79 - 75 69
Gok et al 32 NHBD 89.6 - 89.6 -
HBD 91.4** 91.4**
Sudhindran et al23 NHBD 84 - 80 74
HBD 89** 85** 80**
Brook et al37 NHBD 88 - 84 84
HBD 82** 73* 62*
Gok et al 36 NHBD 92.1 - - -
Sohrabi et al45 NHBD - - 95 -
Muiesan et al46 NHBD 84 - - -
** not statistically significant; * statistically significant;nhbd-non-heart-
beating donor;hbd-heart-beating donor; y-year.
Table 9 - Patient survival in NHBD in England.
1 y(%) 3 y (%) 5 y(%)
Gok et al30 NHBD 87.9 87.9 -
HBD 89.7 89.7
Gerstenkorn et al31 NHBD 93.1 85.3 76.2
Sudhindran et al23 NHBD 91 91 84
HBD 94 92 90
Gok et al36 NHBD 92.1 - -
Muiesan et al46 NHBD 87 - -
nhbd-non-heart-beating donor;hbd-heart-beating donor;y-year.127
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twice as many potential NHBD as there are HBD 58. It has
been suggested that if all potential NHBD kidneys were
retrieved waiting lists for kidney transplantation could be
eliminated59.
Two methods of harvesting of NHBDs have been ad-
vocated to decrease ischemic insult: 1. procurement meth-
ods include in situ intravascular cooling (universal), intra-
peritoneal lavage and cooling (used in the United States),
hypothermic and normothermic partial cardiopulmonary
bypass (used in Spain) and hypothermic extracorporeal
membrane oxygenation (used in Taiwan); and 2. machine
preservation methods include: pulsatile intermittent
perfusion and continuous-and-constant perfusion.
Ischemic injury is almost inevitable in NHBD renal
grafts and primarily results from prolonged hypotension,
cardiac arrest and warm ischemia during the primary warm
ischaemia time (WIT). Development of allograft dysfunc-
tion can result in DGF and PNF.
As far as the NHBD for liver transplantation is concern
Muiesan et al46 based their donor selection on several fac-
tors including age less than 40 years, short intensive care
unit stay, normal liver function tests, short interval from
withdraw of therapy to cardiac arrest, short WIT and good
appearance and perfusion of the liver, as judged by an ex-
perienced transplant surgeon. When the majority of these
parameters were satisfied they provided organs suitable for
bench segmental reduction.
They started the procedure of reduction/spltting as soon
as the recovery team had returned to their centre. Care was
taken to keep the temperature of the University of Wiscon-
sin (UW) solution at 4 C and to avoid re-warming of the
graft. One split procedure was performed. The left lateral
segment was transplanted with 7 h of cold ischemia and
provided excellent immediate function with an International
Normalized Ratio of 1.2 on the second post-operative day.
The adult recipient who received the right lobe split was
transplanted sequentially with a cold ischemia time of 14.3
h and experienced PNF. He died of multi-organ failure af-
ter emergency re-transplantation. Subsequent reduction of
NHBD grafts was performed with transplantation only of
the left lateral segment or left lobe in children46.
The recent largest retrospective study comparing out-
comes of adults recipients of NHBD and HBD hepatic
allografts between 1993 and 2001 based on the United Net-
work of Organ Sharing database confirmed their greater
vulnerability to cold ischemia and the higher incidence of
PNF among a group of 144 NHBD livers60.
Abt et al61 have emphasized the importance of short cold
ischemic time for liver grafts. When the cold ischemic time
was less than 8 h there was 10.8% of graft failure within
60 days of transplantation which increased to 30.4% and
58.3% when the cold ischemia time was greater than 8 and
12 h, respectively. The combination of warm and cold
ischemia in NHBDs appears to make these grafts more sus-
ceptible to biliary complications. A higher incidence of
ischemic cholangiopathy has been reported61,62.
D’Alessandro et al63 also recognized increased incidence
of ischaemic biliary complications in NHBD liver graft re-
cipients from donors older than 40 years of age.
To date there have been no vascular complications and
no evidence of major biliary complications with particular
reference to ischaemic cholangiopathy in these children af-
ter a mean follow-up of 19 months46.
Reddy et al64 described various cytoprotective strategies
involving administration of drugs before cardiac arrest that
have been successfully used in NHBD liver transplantation.
Kidneys from different Maastricht categories recovered
at different rates although they were all similar at 3 months.
Kidneys from NHBDs have undergone more ischemic in-
sult than kidneys from HBDs.This occurs because of the
prolonged early (primary) warm ischemia.
For Maastricht category II donors this the period be-
tween collapse and effective resuscitation, variably effec-
tive resuscitation and the “no-touch” period before
perfusion.
For category III donors after withdrawal of support there
can be an agonal period of hypotension followed by the “
no-touch” period and then perfusion.
Category IV donors are known to be brainstem dead and
are the closest to HBDs. They often arrest in theatre, there-
Table 10 - England centres and variations of non-heart-beating donors programmes.
Centre NHBD technique In situ  Perfusion Immunossupression
Cambridge Laparotomy + aortic cannula UW CSA/AZA/PRED
Leiscester Femoral arteriotomy + DBTL catheter Marshall’s CSA/AZA/PRED or TAC/MMF/PRED
London Kidney-femoral arteriotomy +DBTL Marshall’s CSA/AZA/PRED
Liver- PV cannulation UW TAC/PRED
Newcastle upon-Tyne Femoral arteriotomy + DBTL catheter + MP system Marshall’s Ab induction; TAC/MMF/PRED
UW-University of Wisconsin; DBTL – double-balloon triple-lumen; SKPS-Soltran kidney perfusion solution; PV- portal vein; MP – machine perfusion;CSA-
cyclosporine(7mg/Kg/d); TAC-tacrolimus (0.1mg/kg/d); AZA-azathioprine(1mg/kg/d);PRED – prednisolone(20mg/d reducing to 5 mg/d at 6 months);
MMF – mycophenolate mofetil (2g b.i.d.); Ab – interleukin-2 receptor antibody.128
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fore the primary ischemic time does not include the “no-
touch” period. Thus the primary warm ischemic insult is
likely to be maximal for category II and minimal for IV
with III in-between (II greater than III greater than IV)36.
With maximal primary warm ischemic damage comes
the increasing chance of in situ thrombosis, greater oxy-
gen debt, and increasing acidosis and reduction of cellular
adenosine triphosphate. Viability testing excludes those or-
gans that are so badly damaged they are not likely to func-
tion. As a consequence the prolonged warm ischemia and
reperfusion syndrome is likely to be more severe for kid-
neys from category II donors as opposed to III or IV.
A contrary argument has been put forward that a per-
son who is hospitalized and in an intensive therapy unit
for a protracted period is more likely to have inotropic sup-
port and sepsis which may result in unmeasured
hypoperfusion of kidneys. Therefore, kidneys from a sud-
den collapse (category II) are possibly healthier than those
from a hospitalized patient8.
Gok et al36 demonstrated that the PNF rate is slightly
higher for category II donors (13.5%) than category III
(2.2%) and category IV (0%, p<0.05). In addition DGF in-
cidence is greatest for category II donors (83.8%), less for
category III (67.4%) and best for category IV (0%).
The introduction of pulsatile hypothermic machine-
perfusion of NHBD kidneys, along with viability testing
has resulted in a viable grafts acceptable survival rates with
DGF in recipients. The main advantages of machine
perfusion are the provision of metabolic support via replen-
ishment of ATP by high energy yielding phosphate bonds
from the perfusate (UW solution). Apart from the mechani-
cal flush provided by continuos perfusion, the natural
ischemia-induced capillary vasoconstriction is reversed as
demonstrated by the reduction of intra-renal vascular re-
sistance. This in turn is reflected in lower incidence of de-
layed graft function. Machine perfusion also allows moni-
toring and assessment of viability in an NHBD kidney graft.
Opelz and Terasaki concluded no added advantage of
machine perfusion in HBD65. Machine perfusion fell into
disrepute due to its complex logistics needs66,67,68. It was
also reported in some cases that machine-perfusion was
damaging to the graft69.
Renewed interest in this method of preservation came
about through the use of marginal organs and improved pre-
servative solutions (UW). With the improved solutions, the
incidence of DGF could be reduced using kidneys from
HBDs or those with prolonged cold ischaemia70,71.
Increased demand for viable organs has led to a recent
upsurge in retrieval from the NHBDs. The difficulty expe-
rienced here was the viability of such kidneys. As the pri-
mary warm ischaemia times are prolonged with such do-
nors, viability assessment and organ modulation have been
done by machine perfusing the NHBD kidneys before trans-
plantation  72,73,74,75.
The measurement of intra-renal vascular resistance and
alpha GST is practiced by the Maastricht group, who have
increased their donor pool by 20% 76. Most of the studies
have demonstrated a beneficial effect of pulsatile perfusion
in NHBD kidneys77,78. Machine perfusion has been shown
to improve the graft function in cases of marginal kidneys
as well as those with prolonged cold ischaemic times78.
In the setting of NHBD kidney transplantation, PNF
represents the transplant of an organ irreparably damaged
by warm ischemia. WIT correlates well with graft damage
and there is a point at which organs become non-
viable.There is no strict maximum WIT in NHBDs beyond
which transplantation is contraindicated. Limits of 30 min79,
35 min 25 and 45 min80 have been advocated. Functional
recovery in animal models has been achieved after substan-
tially longer periods of 120 min79 and 140 min81.
Renal transplants with prolonged WIT, that is primary
warm ischemia, demonstrated a relative increase in free
radical generation during NHBD renal transplantation. Use
of traditional tissue injury markers LDH, AST and lactate
and the specific markers of tissue injury Ala-AP and FABP
during kidney transplantation complemented the finding of
free radical injury in NHBD renal transplants. Combined
markers enabled the monitoring of different types of cell
injury. This correlates with the high incidence of acute tu-
bular necrosis and subsequent DGF in NHBD renal trans-
plants.
Reperfusion injury is such that antioxidant strategies
may be of benefit. Potential measures that could be used
are nitric oxide addition82 and free radical scavengers (eg
allopurinol, superoxide dismutase, catalase and dimethyl
sulfoxide) with antioxidant supplementation ( eg
gluthatione, vitamin E and gingko biloba)83,84, cytokine-
chemokine suppressors, adhesion molecule blockers85,86 and
neutrophil-endothelial cell blockade87,88.
The role of free radicals in the pathophysiology of is-
chaemia-reperfusion injury in transplantation is increas-
ingly recognized. Free radical formation appears to occur
in 2 phases, characterized as reperfusion mediated injury
(early and short-lived, that is seconds to minutes) and neu-
trophil mediated injury (late and long-lived, that is min-
utes to an hour). In reperfusion mediated injury adenosine
triphosphate depletion during hypoxia results in the accu-
mulation of hypoxanthine which is coverted to free radi-
cals ( superoxide and hydrogen peroxide radicals) upon
reperfusion by xanthine oxidase activation89. In neutrophil
mediated injury reperfusion results in the activation of neu-
trophil NADPH oxidase and the release of further free radi-129
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cals (superoxide, hydrogen peroxide and hydroxyl radi-
cals)90.
In kidney allograft free radicals can be formed through-
out the renal parenchyma in the intracellular, intravascu-
lar and injury compartments. Ischaemia-reperfusion injury
consist of 2 injury mechanisms namely ischemia charac-
terized as oncotic necrosis and reperfusion injury. In the
clinical setting this damage may delay the recovery of re-
nal function prolong or complicate postoperative recovery
or precipitate immunological reactions involved in the sub-
sequent rejection reaction42.
In practice allowable maximum WIT varies in a quali-
tative manner i.e. a young and previously fit donor may
be allowed a longer WIT than an older donor. The PNF
average rate in the current study was 6.17% which is con-
sistent with the 8 – 15 % reported previously from
NHBDs55,91. This is higher than 2-5% quoted for HBD kid-
neys26,92. Shiroki et al93 claimed that PNF rate is highest in
those NHBD kidneys with warm time of > 30 min. Tanabe
et al94 disagreed stating that warm time bore no relation-
ship to PNF rate but no WIT was > 30 min in their study.
Brook et al  5 showed no episode of PNF in controlled do-
nors with a 20% PNF rate in uncontrolled NHBD kidneys,
indicating an association of warm time with PNF.
The reported incidence of PNF after transplantation us-
ing kidney from NHB donors varies from 4 to 40%, although
most studies do not make distinction between kidneys from
controlled and non-controlled NHB donors when describing
the incidence of PNF22,27,58,75,91,94-99. The PNF is probably a
consequence of ischaemic cortical necrosis5
The perceived risk of PNF and poor graft outcome has
limited the adoption of NHB donor programmes to a rela-
tively small number of transplant centres. Some of these
have used machine perfusion preservation to try and reduce
the risk of PNF, although direct evidence as to its effec-
tiveness is lacking48.
In Newcastle upon-Tyne the introduction of machine
perfusion coincided with a fall in the incidence of PNF
from 54 to 7%21,22. This most probably reflects the ability
to perform viability testing and in Newcastle and other cen-
tres, kidneys are discarded if during machine perfusion in-
tra-renal resistance measurements or levels of S-transferase
are abnormal21,22,74.
DGF occurs more frequently in NHBD (50-100%)92,94
than in HBD (20-60%) kidneys57,91,100. This increased DGF
rate in NHBD kidney is likely to be a consequence of acute
tubular necrosis (ATN) secondary to warm ischaemic dam-
age. Not all DGF is due to ATN, although ATN is the most
common cause and it is not therefore surprising that NHBD
kidneys have a higher incidence of ATN than those from
HBD101.
Brook et al37 showed in controlled donors 48% of DGF
in both NHBD and HBDs whilst the uncontrolled donors
had a significantly higher rate ((88%). It is important to
note that warm time is not the only variable that influences
DGF; duration of pre-transplant dialysis and recipient body
weight also correlate with post-transplant early graft func-
tion 102.
The influence of DGF o kidney allograft survival is con-
troversial. A number of studies have demonstrated poorer
survival in HBDs with DGF 103,104,105 compared with HBDs
with immediate function, while others authors have re-
ported no such effect, independent of acute rejection106,107.
Brook et al37 demonstrate that serum creatinine is sta-
ble in recipients of kidneys from NHBDs from 3 months
to 7 yr post-transplant. There is disagreement in the litera-
ture over NHBD post-transplant renal function. In some
studies NHBD kidneys achieved early serum creatinine lev-
els in the normal range26,49,58,108,109 whist others studies re-
ported poor graft function than HBD in both the short and
medium term73,91.
NHBDSs kidneys in the medium term achieve a good
level of renal function with a mean serum creatinine at 12
months of 174 umol/L 76 and a median of 199 umol/L at
18 months49. So far, there is no evidence of accelerated de-
terioration of NHBDs kidneys because of a reduced func-
tioning glomerular mass due to initial ischaemic damage.
Acute rejection is thought to occur more frequently and
with greater severety in kidneys with prolonged ischaemia
and DGF110. This may be a result of the increased rate of
detection of sub-clinical rejection because biopsies are
taken more frequently in the presence of DGF111.
Brook et al34, demonstrated for the first time that the
high rate of DGF associated with renal transplantation from
NHBDs does not lead to poor graft survival when compared
with HBDs with DGF.
In recent years there has been a re-evaluation of the use
of NHBDs for renal transplantation. While some studies
have shown poorer graft survival for NHBD kidneys103,105,
others have demonstrated favourable graft survival com-
pared with HBDs25,91,112,113. This is despite the detrimental
effects of warm ischaemic damage in NHBDs with conse-
quent high rates of DGF.
Brook et al37 reported that despite the detrimental ef-
fects of long WIT in NHBD with consequent high rates of
PNF and DGF, there have been favourable comparisons
with HBD in terms of graft survival also demonstrating that
NHBD kidneys display parity with HBD meeting the Brit-
ish Transplant Society guidelines114 for HBD allograft sur-
vival at 1 and 5 yr of 80 and 60% respectively.
It would seen that long ischaemic time causes revers-
ible graft problems at an early stage in terms of PNF and130
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DGF. Later NHBD grafts appear to perform at least as well
as those from HBDs.
Finally, as previously published there are many ways
to make transplantation demand compatible with organ sup-
ply  115,116,117,118,119,120. We have always to bear in mind that
the gap between demand and supply of organs for trans-
plantation continues to grow. One solution to this problem
has been to return to the practice of using grafts from
NHBDs. The challenge of NHBD transplantation is to mini-
mize the first period of warm ischaemia and the consequent
reperfusion injury.
CONCLUSION
NHBDs kidney transplants are associated with allograft
dysfunction as PNF and DGF which is related to primary
warm ischaemic injury. This warm ischaemia is more del-
eterious in uncontrolled than controlled NHBDs.
Kidney transplant from NHBDs can be performed suc-
cessfully. The significant degree of warm ischemic injury
suffered by NHBD kidneys leads to a high incidence of
DGF but the data available so far suggest that this does not
adversely influence long-term graft survival.
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